Successful treatment with dupilumab in a patient with severe, difficult to treat atopic dermatitis: Beware of symptomatic adrenal insufficiency due to abrupt discontinuation of potent topical corticosteroids

Ariens, Lieneke F.M.; van der Schaft, Jorien; Stades, Aline M.E.; van de Woestijne, Anthonie A.; De Bruin-Weller, Marjolein S.

doi:https://doi.org/10.2340/00015555-2936

Successful treatment with dupilumab in a patient with severe, difficult to treat atopic dermatitis: Beware of symptomatic adrenal insufficiency due to abrupt discontinuation of potent topical corticosteroids

DSpace/Manakin Repository

Successful treatment with dupilumab in a patient with severe, difficult to treat atopic dermatitis: Beware of symptomatic adrenal insufficiency due to abrupt discontinuation of potent topical corticosteroids

Ariens, Lieneke F.M.; van der Schaft, Jorien; Stades, Aline M.E.; van de Woestijne, Anthonie A.; De Bruin-Weller, Marjolein S.

(2018) Acta Dermato-Venereologica, volume 98, issue 6, pp. 601 - 602

(Editorial)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Administration, Cutaneous, Adrenal Cortex Hormones/administration & dosage, Adrenal Insufficiency/blood, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Betamethasone/administration & dosage, Biomarkers/blood, Dermatitis, Atopic/diagnosis, Drug Substitution/adverse effects, Humans, Hydrocortisone/administration & dosage, Male, Middle Aged, Remission Induction, Severity of Illness Index, Treatment Outcome, Dermatology, Case Reports, Journal Article

DOI: https://doi.org/10.2340/00015555-2936

ISSN: 0001-5555

Publisher: Medical Journals Sweden AB

Note: Funding Information: The patient described in this case report participated in 2 phase III dupilumab clinical trials sponsored by Regeneron.

(Peer reviewed)